You can more-or-less pinpoint the decline of the pharmaceutical sales rep profession to the day that the first DTC advertising for prescription drugs started.
Here is another good example in todays news:
Glaxo's HIV-Drug Ads Draw Critics
[These ads are a sign of desperation insofar as GILD has eaten GSK’s lunch in the HIV market (#msg-26915314).]
http://online.wsj.com/article/SB121961241070167309.html
›By JEANNE WHALEN
August 25, 2008
GlaxoSmithKline PLC, one of the biggest sellers of drugs to fight the AIDS virus, is drawing criticism over magazine ads in the U.S. that patient-support groups say attempt to scare patients away from trying newer drug regimens.
Bob Huff, antiretroviral project director at Treatment Action Group, an advocacy group in New York, says he complained to Glaxo a few months ago about an ad that shows shark-infested waters with the message: "Don't take a chance -- stick with the HIV medicine that's working for you." Mr. Huff calls the ad offensive and aimed at instilling fear in patients. The ads carry Glaxo's logo but don't promote specific drugs.
In another ad in Poz, a monthly magazine for patients infected with AIDS, Glaxo promotes its protease inhibitor Lexiva and advises patients to ask their doctor, "Will the HIV medicine make my skin or eyes turn yellow?" Other protease inhibitors have been associated with that side effect.
The AIDS Healthcare Foundation, a nonprofit group in Los Angeles that provides health care to patients who test positive for HIV, the human immunodeficiency virus that causes AIDS, says it sent a letter last month to the Department of Health and Human Services complaining about Glaxo's advertisements. The group says it hasn't yet received a response.
A spokesman for HHS said the department hadn't received the letter.
Glaxo says the ads are "educational" and appropriate. "While we acknowledge that some people may find the headline and imagery of the materials to be provocative, GSK stands firmly behind the ads and their underlying message: Patients considering changing HIV therapy ought to consult closely with their physician to fully understand the near and potential long-term health implications of such changes," Marc Meachem, a company spokesman, said in an emailed statement.
The ads are part of a larger trend of drug companies taking aim at rival HIV drugs, hinting at side effects and other drawbacks, experts say.
Among other controversial campaigns, a recent print ad from Bristol-Myers Squibb shows an image of a toilet and says, "Ask your doctor if there are HIV medications with a low risk of diarrhea." That is a side effect associated with the HIV drug Kaletra made by Abbott Laboratories. Bristol-Myers' antiviral drug Reyataz isn't commonly associated with diarrhea. Brian Henry, a spokesman for Bristol-Myers, said the ad is appropriate. Abbott spokeswoman Melissa Brotz said "Kaletra has a well-established side-effect profile and profound and sustained effectiveness in combating HIV."
Such comparison ads are common elsewhere. But the pharmaceutical industry traditionally sold HIV drugs with images of hope and by explaining the benefits of their treatments. The tough new tack has some patient groups unsettled, saying it could scare off patients.
A development fueling the sharp-elbows advertising: The market for HIV medicines has grown crowded, and companies want to protect their market share. [Moreover, the immense success of newer drugs has turned AIDS into a chronic condition, which raises the stakes for brand-switching.]
"Treatments have become so comparable, so [companies] are really trying to split hairs to have a marketing advantage," says Regan Hoffman, editor of Poz, which has a circulation of 150,000. Ads for HIV treatments usually run in magazines that focus on the disease, or sometimes on billboards and street posters.
Glaxo is one of the world's biggest sellers of HIV drugs, but its medicines are relatively old and losing market share. Its share of the $11 billion global market has fallen sharply in recent years, to about 25% today from about 39% in 2004, according to IMS Health. [See the annotations in the prologue to this post.] During that time, Glaxo launched few new HIV treatments.
Some of Glaxo's biggest HIV drugs, including Combivir and Trizivir, have been losing ground to newer treatments such as Truvada from Gilead Sciences Inc. and Atripla from Gilead and Bristol-Myers Squibb Co. AIDS groups say Glaxo's ads appear aimed at stopping patients from abandoning Glaxo drugs for others.
Dan Kuritzkes, a professor at Harvard Medical School who also treats HIV-positive patients at Brigham & Women's Hospital in Boston, says he worries that the shark ads "scare patients into resisting their doctor's advice."
Glaxo's Mr. Meachem says this isn't the case. The advertising is "just as likely to encourage a patient to stay with another medicine as it is one of our own, assuming that the medicine is working for a patient and is well-tolerated," he says.
However, Mr. Meachem says he is aware of the groups' concerns. The shark-themed ad campaign "ends this September, and, as always, we will take all the community feedback we have received into consideration for future campaigns," he says.‹